Companies /Healthcare

Avalo Therapeutics Inc

NASDAQ: AVTX Biotechnology
$6.96
▼ $0.17 (−2.38%) today
Markets open · 2:16pm ET

AVTX at a Glance

Valuation
Market cap
$426.2M
Profitability
Revenue (TTM)
$59,000
EPS (TTM)
$-2.15
Price
52-week range
$7 – $24
Street target
$34.80

Headquartered in Wayne, PA Fiscal year ends December NASDAQ: AVTX avalotx.com

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that target the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases.

Its lead candidate is abdakibart (AVTX-009), a humanized IgG4 monoclonal antibody that binds IL-1β with high affinity and neutralizes it. Following positive Phase 2 LOTUS trial results in hidradenitis suppurativa (HS), abdakibart is being prepared for a registrational Phase 3 program. HS is a chronic inflammatory skin condition estimated to affect 1-4% of the global population. Phase 3 initiation is planned for the first half of 2027, after FDA feedback expected by year-end 2026.

Avalo is also developing AVTX-010, a next-generation, Fc-engineered, long-acting anti-IL-1β antibody designed to extend half-life while preserving abdakibart's pharmacology. An IND submission is targeted for the first half of 2027 for potential use in HS and other inflammatory diseases.

The company is pursuing additional IL-1β-driven indications. It held [USD:462800000] in cash, cash equivalents and investments as of September 30, 2026, which it expects to fund operations into 2029. Updated

AVTX Coverage

Frequently Asked Questions

What does Avalo Therapeutics do?

Avalo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that target the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases.

What is the AVTX stock price target?

The Wall Street consensus 12-month price target for AVTX is $34.80.